子类别 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 邻近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群统计 近3年内发表的文件:74(14.51%) 含全文笔数:443(86.86%) 文件下载次数统计 下载大于0次:443(100.00%) 下载大于100次:425(95.94%) 全文下载总次数:177154(3.31%) 最后更新时间: 2024-11-28 16:05 上传排行 数据加载中..... 下载排行 数据加载中..... 最近上传 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (选择年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (选择月份) January February March April May June July August September October November December 或输入年份:

由新到旧排序 由最旧的开始

显示项目176-200 / 510. (共21页) << < 3 4 5 6 7 8 9 10 11 12 > >> 每页显示[10|25|50]项目

日期	题名	關聯
2018-10	Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
2018-10	NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
2018-10	The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
2018-10	Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1	Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.
2018-10	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P.
2018-10	Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD.
2018-09	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286.
2018-08-24	BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor	Cancer Science. 2018 Nov;109(11):3591-3601.
2018-07	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients	Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598.
2018-06	Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma	Annals of Oncology. 2018 Jun;29(6):1402-1408.
2018-06	The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
2018-06	Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
2018-06	Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150.
2018-06	Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004.
2018-06	Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151.
2018-05	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127.
2018-05	A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers	Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556.
2018-05	A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204.
2018-04	The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis	Cancer Research and Treatment. 2018 Apr;50(2):562-574.
2018-04	Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study	Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093.
2018-03	Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use	Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183.
2018-03	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy	Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31.
2018-02-01	Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development	OncoImmunology. 2018 Feb 1;7(5):Article number e1424612.
2018-02	Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.
2018-02	Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459.

显示项目176-200 / 510. (共21页) << < 3 4 5 6 7 8 9 10 11 12 > >> 每页显示[10|25|50]项目